The cardiovascular system is the first functional organ system to develop in the vertebrate embryo, reflecting its critical role during normal development and pregnancy. This Adverse Outcome Pathway focuses on the regulation and disruption of vasculogenesis-angiogenesis during embryonic development via disruption of the Vascular Endothelial Growth Factor (VEGF) signaling pathway. This pathway is a critical regulatory system for assembly of embryonic blood vessels. Genetic studies have shown that perturbing the VEGF signaling system can invoke varying degrees of adverse consequences, ranging from congenital angiodysplasia to fetal malformations and embryolethality. This AOP is referred to as AOP 43 in the Collaborative Adverse Outcome Pathway Wiki (AOP-Wiki).
Disruption of VEGFR signaling leading to developmental defects
Working paper
Share
Facebook
Twitter
LinkedIn
Abstract
In the same series
-
30 June 2025193 Pages
-
Working paper30 June 2025250 Pages
-
30 June 2025329 Pages
-
Working paper30 June 2025270 Pages
-
Working paper26 June 202599 Pages
-
Working paper12 December 2023155 Pages
Related publications
-
2 July 2026115 Pages
-
Report2 July 202632 Pages
-
2 July 202615 Pages
-
Report
Assay for the Detection of Glucocorticoid Receptor Agonist and Antagonist Activity of Chemicals
2 July 202634 Pages -
Report
Assays addressing the Adverse Outcome Pathway key event on covalent binding to proteins
2 July 202663 Pages -
Report
Assays addressing the Adverse Outcome Pathway Key Event on Keratinocyte activation
2 July 202698 Pages